Global X Japan Co. Ltd. Takes Position in Merck & Co., Inc. $MRK

Global X Japan Co. Ltd. purchased a new position in shares of Merck & Co., Inc. (NYSE:MRK) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 67,892 shares of the company’s stock, valued at approximately $7,146,000.

Several other institutional investors have also recently added to or reduced their stakes in MRK. Abound Wealth Management increased its holdings in shares of Merck & Co., Inc. by 6.8% in the fourth quarter. Abound Wealth Management now owns 1,554 shares of the company’s stock valued at $164,000 after purchasing an additional 99 shares during the period. Pine Haven Investment Counsel Inc lifted its holdings in shares of Merck & Co., Inc. by 0.7% during the fourth quarter. Pine Haven Investment Counsel Inc now owns 14,137 shares of the company’s stock worth $1,488,000 after purchasing an additional 105 shares during the period. Lake Street Private Wealth LLC grew its position in Merck & Co., Inc. by 2.1% in the 4th quarter. Lake Street Private Wealth LLC now owns 5,203 shares of the company’s stock valued at $548,000 after buying an additional 109 shares during the last quarter. One Charles Private Wealth Services LLC increased its stake in Merck & Co., Inc. by 3.3% in the 3rd quarter. One Charles Private Wealth Services LLC now owns 3,464 shares of the company’s stock valued at $291,000 after buying an additional 111 shares during the period. Finally, Fragasso Financial Advisors Inc increased its stake in Merck & Co., Inc. by 1.0% in the 4th quarter. Fragasso Financial Advisors Inc now owns 11,502 shares of the company’s stock valued at $1,211,000 after buying an additional 115 shares during the period. Institutional investors and hedge funds own 76.07% of the company’s stock.

Insider Buying and Selling at Merck & Co., Inc.

In related news, CMO Chirfi Guindo sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $118.41, for a total transaction of $1,184,100.00. Following the transaction, the chief marketing officer owned 70,615 shares of the company’s stock, valued at approximately $8,361,522.15. This represents a 12.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Johannes Jacobus Oosthuizen sold 15,000 shares of the business’s stock in a transaction on Friday, February 6th. The shares were sold at an average price of $121.87, for a total value of $1,828,050.00. Following the completion of the transaction, the insider owned 21,197 shares of the company’s stock, valued at $2,583,278.39. This trade represents a 41.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 320,176 shares of company stock valued at $38,281,735. 0.13% of the stock is owned by company insiders.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck agreed to acquire Terns Pharmaceuticals for about $6.7 billion to add TERN‑701, an investigational CML drug that could meaningfully strengthen Merck’s hematology/oncology lineup ahead of Keytruda’s patent cliff. Merck to Boost Oncology Pipeline With $6.7B Terns Buyout, Stock Up
• Positive Sentiment: Citi raised its price target on MRK to $125 (from $120), reflecting continued analyst recognition of Merck’s profitability and strategic M&A. Citi Raises its Price Target on Merck & Co. (MRK) to $125 from $120
• Positive Sentiment: Agilent received FDA approval for the PD‑L1 IHC 22C3 pharmDx as a companion diagnostic for Keytruda in esophageal/GEJ carcinoma—supportive for continued clinical use of Keytruda where indicated. This can help sustain Keytruda demand in approved indications near-term. Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx
• Neutral Sentiment: Heightened investor interest and searches on Merck point to increased attention and volume as the market digests the deal and guidance; this can amplify intraday moves but is not directional on fundamentals. Investors Heavily Search Merck & Co., Inc. (MRK)
• Neutral Sentiment: Merck held an M&A investor call and provided materials/transcript — useful for detail but mainly confirms terms and rationale rather than changing the deal. Merck & Co., Inc. (MRK) M&A Call Transcript
• Negative Sentiment: Analysts and media note potential rival interest in Terns; William Blair and others suggest the $53/shr offer may undervalue Terns’ upside, implying Merck could face a bidding contest or need to increase the price. That raises transaction risk and potential dilution/cost. Merck’s $6.7 billion Terns acquisition may face rival interest: Analyst
• Negative Sentiment: An investor‑rights law firm is investigating whether Terns shareholders are getting fair value, which can delay closing or lead to litigation/negotiation that complicates the deal timeline and integration. Terns Pharmaceuticals Investor Alert

Merck & Co., Inc. Trading Down 0.4%

Shares of MRK stock opened at $118.90 on Friday. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $125.14. The company has a quick ratio of 1.30, a current ratio of 1.54 and a debt-to-equity ratio of 0.89. The business has a fifty day simple moving average of $116.43 and a 200-day simple moving average of $101.56. The stock has a market cap of $293.97 billion, a P/E ratio of 16.33, a P/E/G ratio of 2.31 and a beta of 0.27.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.01 by $0.03. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The company had revenue of $16.40 billion for the quarter, compared to the consensus estimate of $16.19 billion. During the same quarter in the prior year, the firm earned $1.72 earnings per share. The company’s revenue for the quarter was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, analysts forecast that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be given a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio is currently 46.70%.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Bank of America boosted their price target on shares of Merck & Co., Inc. from $105.00 to $120.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Deutsche Bank Aktiengesellschaft raised Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 price objective on the stock in a report on Friday, February 13th. Zacks Research raised Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 17th. Royal Bank Of Canada initiated coverage on Merck & Co., Inc. in a report on Wednesday, February 25th. They issued an “outperform” rating and a $142.00 price target for the company. Finally, Morgan Stanley increased their price objective on Merck & Co., Inc. from $100.00 to $102.00 and gave the stock an “equal weight” rating in a research report on Friday, December 12th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and an average price target of $127.13.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.